Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Breast 2Plasma cell 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 49Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × CB-839 × Myeloid × Clear all
NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
28 enrolled 8 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡